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ABSTRACT 
Antenatal malaria screening with a rapid diagnostic test (RDT) and treatment only of RDT-
positive women may potentially prevent low birthweight resulting from malaria. The 
consequences of subpatent antenatal infections below the detection limit of RDTs are 
incompletely understood. In Malawi, pregnant women of any gravidity were tested at each 
antenatal visit for P. falciparum using RDT and PCR and followed until delivery. Associations 
between antenatal infections and delivery outcomes were assessed with Poisson regression or 
ANOVA. Compared to women with no detected antenatal P. falciparum infections, women with 
RDT-positive infections delivered babies with lower mean birthweights: 2960 vs 2867 grams[g] 
(mean difference[MD]: -93g; 95% confidence interval[CI]: -27,-159; p=0.006); this was not 
observed among women with only subpatent infections (mean: 3013g; MD: +54; 95% CI: -
33,+140; p=0.2268). These differences were apparent early in pregnancy: At second trimester 
enrollment, compared to uninfected women, RDT-positive women delivered babies with lower 
mean birthweight (MD: -94g; 95% CI: -31,-156; p=0.003), but women with subpatent infections 
did not (MD: +36g; 95% CI: -49,+122; p=0.409). Subpatent antenatal P. falciparum infections 
were not associated with adverse delivery outcomes. The association of patent infections at 
enrollment with low birthweight suggests the importance of early-pregnancy P. falciparum 
prevention.  
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Background 
Innovative approaches are continually needed to prevent placental malaria. In sub-Saharan 
Africa, placental P. falciparum infection causes low birth weight (LBW), small for gestational age 
(SGA), and preterm (PT) births; the risks of these adverse outcomes are mitigated by 
intermittent preventive therapy with sulfadoxine-pyrimethamine (IPTp-SP), which in Africa is 
widely recommended[1] but sub-optimally administered[2, 3] and continually threatened by 
resistance to SP.[4-6] One possible alternative strategy to IPTp-SP is intermittent antenatal 
screening for parasites with rapid diagnostic tests (RDTs) and the treatment of RDT-positive 
women with antimalarials (known as intermittent screening and treatment during pregnancy, 
or ISTp). Although ISTp results in more maternal antenatal infections[7], ISTp with artemisinin 
combination therapies was non-inferior to IPTp-SP to prevent LBW in two trials in low SP-
resistance areas in West Africa,[7, 8] and ISTp with dihydroartemisinin-piperaquine was inferior 
to IPTp-SP in preventing parasitemia at delivery in Kenya and Malawi.[9] [10] Although WHO 
does not currently recommend ISTp as an alternative to IPTp-SP,[11] it is either being 
implemented[12] or planned[13] in low-transmission settings. With broad declines in malaria 
transmission[14] and increasing resistance to SP,[15] ISTp may offer an alternative to IPTp-SP in 
some epidemiologic settings for the prevention of LBW in malaria-endemic Africa. 
 
However, there exists concern that the ISTp approach may be undermined by low-density 
antenatal infections that are undetected by screening tests and therefore remain untreated. 
The lower limits of detection for P. falciparum vary by diagnostic method, and are generally 
considered highest for light microscopy, slightly lower for RDTs, and lowest for molecular 
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detection assays like PCR. Antenatal subpatent infections are defined as negative by light 
microscopy or RDTs but positive by PCR, and result from parasite densities which fall between 
the limits of detection of diagnostic methods. In cross-sectional studies, subpatent infections 
have been associated with pregnancy outcomes: they have been associated with maternal 
anemia during pregnancy [16] or at delivery,[17] and with lower birthweight when detected at 
delivery.[18, 19] These cross-sectional studies provide limited ability to infer causality, but only 
a limited number of longitudinal studies have investigated subpatent infections and delivery 
outcomes. In Benin, these submicroscopic infections were associated with higher risks of LBW 
and preterm birth[20] and in Malawi with an increased risk of placental malaria, but not with 
adverse maternal or fetal outcomes.[21] In one Ghanaian study, sub-RDT (or subpatent) 
antenatal infections were not associated with LBW.[22] Before ISTp can be considered as a 
potential viable alternative to IPTp in any settings, the potential impact of subpatent infections, 
more especially sub-RDT infections, on a variety of endpoints in multiple cohorts needs to be 
determined. 
 
We investigated the impact of subpatent (RDT-negative/PCR-positive) P. falciparum infections 
in a cohort of Malawian women who were enrolled in a trial and randomized to the arm that 
received ISTp using a commercial RDT that detects the Plasmodium antigens HRP2 and 
pLDH.[10] We tested the impact of antenatal subpatent infections on maternal and newborn 
birth outcomes, including birthweight, gestational age, placental malaria, and maternal 
hemoglobin at delivery. We hypothesized that, relative to uninfected women, the presence of 
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subpatent antenatal infections would be associated with a decrease in mean birthweight and 
with growth retardation, in particular in paucigravidae. 
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Methods 
Study cohort 
We used specimens collected from participants in a published randomized clinical trial in 
Malawi conducted between 2011-14 that compared IPTp-SP with ISTp-DP (PACTR.org: 
201103000280319; ISCRTN.com: 69800930).[10] Briefly, women of all gravidae presenting for 
antenatal care between 16-28 weeks gestation to three health clinics in Southern Malawi were 
eligible to participate. Women were randomized (1:1) to either intervention, which was 
administered open-label. Prior to delivery, all women were seen again at 2 to 3 additional 
scheduled visits and encouraged to return for unscheduled visits if they felt unwell between 
scheduled visits.  
 
We used specimens only collected from women allocated to receive ISTp. At each visit, venous 
blood was collected from these women for parasite detection by light microscopy, RDT, and 
PCR. Those who tested positive by RDT were administered a standard 3-day course of 
dihydroartemisinin-piperaquine.  
 
Outcome assessments 
At delivery, maternal venous blood was tested for parasites using the same methods; placental 
histology was assessed for placental malaria using standard methods;[23] placental blood from 
the maternal side was tested for malaria parasites using light microscopy, RDT, and PCR; and 
newborns were weighed and gestational age was assessed using a modified Ballard score.[24] 
Ac
ce
pte
d M
an
us
cri
pt
 
8 
 
Maternal hemoglobin was measured from venous blood using the Hemocue 301; a hemoglobin 
concentration < 11g/dL defined maternal anemia. 
 
Birthweights obtained more than 24 hours after birth were corrected for the physiologic fall in 
weight in breastfed children[25] to obtain a corrected birthweight, which was used in all 
analyses. Birthweights were measured using digital weigh scales reporting weight to the 
nearest 10g. Low birthweight (LBW) was defined as < 2500g. We estimated gestational age 
using the following hierarchy, which varied between participants: ultrasound at enrollment, 
newborn Modified Ballard’s Score clinical exam within 96 hours of delivery, last menstrual 
period, or fundal height at enrollment. Preterm (PT) birth was defined as delivery at less than 
37 weeks. Small for gestational age (SGA) was defined as a birthweight below the tenth 
percentile for the gestational age and sex of the newborn, using a Tanzanian reference 
population; from this reference, z-scores of birthweight for gestational age were computed.[26] 
 
Laboratory procedures 
Microscopy was performed at a central laboratory at the University of Malawi by two 
independent readers who assessed 200 high powered fields of thick smear preparations. A 
positive microscopic test was defined as the presence of any asexual Plasmodium spp. 
parasites. RDT testing was performed at point-of-care using the HRP2/pLDH combination RDT 
(FirstResponse Malaria pLDH/HRP2 Combo Test, Premier Medical Corporation Ltd, USA) per the 
manufacturer’s recommendation. A positive test was defined as the presence of the control 
band as well as at least one HRP2 or pLDH band. Placental sections of 2.5cm3 were used for 
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histologic analysis, for which hematoxylin and eosin staining was used to score for the presence 
of parasites, parasite pigment, and intervillous inflammation;[23] histologic analysis was 
performed by a trained technician masked to microscopy, RDT, and outcome data. 
 
PCR detection of parasites was performed using a real-time PCR assay[27] targeting the P. 
falciparum lactate dehydrogenase gene (pfldh) in genomic DNA extracted from dried blood 
spots using Chelex-100. Real-time PCR assays were performed in duplicate in 384-well reaction 
plates on a BioRad CFX384 platform, threshold lines were set manually, and each reaction plate 
included gDNA from parasite strain 3D7 as a positive control. PCR detection was performed by 
personnel masked to microscopy, RDT, and outcome data. 
 
Data analyses  
The main exposure of interest was subpatent (i.e. RDT-negative and PCR-positive) infection 
with P. falciparum. Exposure classifications were i) infections at antenatal enrollment, based 
upon RDT and PCR (uninfected v. RDT-positive v. subpatent) and ii) cumulative antenatal 
infections (never infected v. RDT-positive infections only v. subpatent infection only). The 
continuous outcomes analyzed were maternal hemoglobin at delivery, birthweight, gestational 
age, and birthweight-for-age Z-score; the dichotomous outcomes analyzed were LBW, SGA, PT, 
the composite endpoint of LBW, SGA, or PT, placental malaria (parasites detected by 
microscopy, RDT, PCR, or histology in placental specimens), and maternal anemia at delivery 
(hemoglobin concentration < 11g/dL). We compared continuous outcomes using oneway 
ANOVA and expressed results as the mean difference and corresponding 95% confidence 
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intervals (CIs). We compared dichotomous outcomes using Poisson regression and expressed 
results as Risk Ratios (RRs) with 95% CIs. We compared proportions of placental histologic 
features between groups using the chi-squared test. All analyses were conducted overall (all 
gravidae) and by gravidity strata (pauci- or multigravidae). The analysis involving all gravidae, 
included gravidity as a binary co-variable (pauci- or multigravidae). All statistical analyses were 
performed with Stata/IC (v14, StataCorp, College Station, TX, USA). 
   
Ethical statement 
The clinical study was approved by the ethical review boards of the National Health Sciences 
Research Committee, Malawi, and the Liverpool School of Tropical Medicine. Testing of 
specimens was approved by the University of North Carolina.  
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Results 
Epidemiology of antenatal infections 
Of 923 women allocated to the ISTp study arm, the mean (SD) age was 22.5 (5.1) years, the 
mean (SD) estimated gestational age at enrollment was 146.8 (23.3) days, 34% were 
primigravidae, and 18% had slept under a bednet the previous night. At enrollment, 51.2% 
(n=473) were uninfected, 34.5% (n=318) had an RDT-positive infection, and 14.3% (n=132) had 
a subpatent infection. The prevalence of RDT-positive infections declined at subsequent 
scheduled visits to 6.1% at the 1st, 7.0% at the 2nd, and 10.3% at the 3rd. In contrast, the 
prevalence of subpatent infections remained largely unchanged at these visits: 12.5% (1st), 
13.2% (2nd), and 14.3% (3rd) (Figure 1A). At unscheduled visits, the prevalence of RDT-positive 
infections was higher than that of subpatent infections (Figure 1A). 
 
Overall, women had RDT-positive infections on up to 4 separate visits, and subpatent infections 
on up to 6 separate visits (Figure 1B). Of the 923 women, 474 (51.4%) had at least 1 RDT-
positive infection and 323 (35%) had at least 1 subpatent infection. Compared with 
multigravidae, paucigravidae did not have more subpatent infections (pauci: 36.4%, multi: 
32.7%; p = 0.47).  
 
Maternal and newborn outcomes 
The overall mean (SD) birthweight was 2921g (423), mean (SD) maternal hemoglobin at delivery 
was 12g/dL (1.56), mean (SD) gestational age was 38.1 weeks (2.4), and mean (SD) birthweight-
for-age Z-score was 0.14 (0.94) (Supplemental Table 1). The prevalence of LBW was 12% 
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(98/818), the composite LBW/SGA/PT 29.9% (254/849), placental malaria 40.9% (337/825), and 
maternal anemia at delivery 24% (196/817) (Supplemental Table 2). 
 
Associations of birth outcomes with infections at antenatal enrollment  
Among all gravidae, compared to uninfected women, those with RDT-positive infections at 
enrollment delivered babies with similar gestational age but lower mean birthweights (mean 
difference [MD]: -94g; 95% confidence interval [CI]: -156, -31; p = 0.0033) and lower 
birthweight-for-age Z-scores (MD: -0.17; 95% CI: -0.31, -0.03; p = 0.0194); in contrast, 
subpatent infections were not associated with any of these outcomes (Figure 2). In 
paucigravidae, RDT-positive infections were associated with lower maternal hemoglobin at 
delivery (MD: -0.33g/dL; 95% CI: -0.63, -0.03; p = 0.0308), but not significantly associated with 
birthweight or Z-scores (Supplemental Table 1). On dichotomized outcomes, compared to 
uninfected women at enrollment, the presence of an RDT-positive infection was associated 
with an increased prevalence of LBW (RR 1.67; 95% CI: 1.08 – 2.58) and placental malaria (RR 
1.73; 95% CI: 1.36 – 2.19); subpatent infections were not associated with any increased risk of 
adverse birth outcom s, including LBW (RR 0.93; 95% CI: 0.46 – 1.87) (Figure 3; Supplemental 
Table 2). Among paucigravidae specifically, relative to uninfected women, an RDT-positive 
infection was only associated with an increased prevalence of placental malaria (RR 1.81; 95% 
CI: 1.38 – 2.37). In these women, a subpatent infection was not significantly associated with any 
outcome, including LBW (RR 0.64; 95% CI: 0.25 – 1.66) (Figure 3; Supplemental Table 2). 
 
Associations of birth outcomes with cumulative antenatal infections 
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Compared to infants born to women who were never infected, women with RDT-positive 
infections during pregnancy delivered babies with lower birthweight (MD: -93g; 95% CI: -159, -
27; p = 0.0061) and birthweight-for-age Z-scores (MD: -0.20; 95% CI -0.34, -0.05; p = 0.008); in 
contrast, neither outcome was associated with having suffered only subpatent infections 
(Figure 2; Supplemental Table 3). In analyses stratified by gravidity, compared to women who 
were never infected, women with RDT-positive infections had non-significant reductions in 
mean birthweight amongst both paucigravidae (MD: -39g; 95% CI: -129, +50; p = 0.3916) and 
multigravidae (MD: -79g; 95% CI: -184, +25; p = 0.1369), while women with only subpatent 
infections had non-significant increases in birthweight (Supplemental Table 3). Notably, there 
were no differences in gestational age between women who were never infected and those 
who either suffered RDT-positive or only subpatent infections.  
 
There was no statistically-significant difference in the prevalence of LBW between those who 
were never infected (9.7%), those with RDT-positive infections (14.7%; RR 1.28, 95% CI: 0.78 – 
2.08), and those with subpatent infections only (7.6%; RR 0.78, 95% CI: 0.38 – 1.60) (Figure 3; 
Supplemental Table 4). The prevalence of placental malaria was 23.6% in women who were 
never infected antenatally, 51.6% in those with RDT-positive infections at least once (RR 1.93, 
95% CI 1.43 – 2.59), and 37.6% in those with subpatent infections only (RR 1.59, 95% CI 1.10 – 
2.30) (Figure 3; Supplemental Table 4). Among the 334 women with placental malaria, 
intervillous inflammation was not associated with infections at enrollment or with cumulative 
antenatal infections, but malaria pigment was more common among women with RDT-positive 
infections at enrollment (66.7%; 112/168) compared to women not infected (24.4%; 30/123) or 
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with subpatent infections (20.9%; 9/43; p < 0.001) (Table 1). Similarly, malaria pigment was also 
more common amongst women with RDT-positive infections at least once antenatally (61%; 
136/223) compared to those who were never infected (8.9%; 5/56) or those with only 
subpatent antenatal infections (18.2%; 10/55; p < 0.001).   
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Discussion 
In our cohort of over 800 delivering women in a malaria-hyperendemic setting in Malawi, PCR-
positive sub-patent antenatal P. falciparum infections which were below the limit of detection 
of an RDT and remained therefore untreated, were not consistently associated with adverse 
maternal or newborn outcomes. In contrast, RDT-positive infections as expected were 
associated with lower birthweights and lower birthweight-for-age Z-scores, suggesting that 
antenatal P. falciparum infections that remain undetected by a commercial RDT targeting the 
pLDH/HRP2 antigens are not associated with an increased risk of adverse clinical birth 
outcomes. 
 
This lack of an association between morbidity and subpatent infections was evident in 
multigravidae as well as paucigravidae, despite the fact that paucigravid women are at higher 
risk of malaria infections and their consequences. Our results are consistent with a prior 
Ghanaian trial of ISTp with artemether-lumefantrine in paucigravidae, which also showed no 
associations between subpatent infections and birthweight or maternal hemoglobin 
concentration.[22] Taken together, these data, coupled with our analyses of a broad range of 
outcomes in a cohort with a high prevalence of subpatent infections, suggest that untreated 
subpatent infections do not cause fetal growth restriction or maternal anemia in semi-immune 
pregnant women in highly endemic areas of sub-Saharan Africa. Furthermore, our data do not 
support the hypothesis that the non-superiority of ISTp-DP to IPTp-SP was mainly the result of a 
failure to detect and treat these subpatent infections. The continued efficacy of IPTp-SP to 
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improve birthweight may be the result of off-target or antibacterial effects of SP or cryptic 
factors. 
 
Unlike a recent study in Benin,[20]we found no specific association between subpatent 
infections at antenatal enrollment and an increased prevalence of LBW or PT. Both our and the 
study in Benin enrolled women < 24 weeks gestation and detected parasites using real-time 
PCR assays, but key differences are the use of IPTp with SP in Benin and the differing definitions 
of subpatent between the two studies (submicroscopic in Benin, sub-RDT in our study). Both of 
these differences might be expected to exacerbate the biological effects of subpatent infections 
in our study: the absence of IPTp in our study would have allowed subpatent infections to 
persist during pregnancy, and the higher limit of detection of parasites for our RDT 
(approximately 200 parasites/ uL)[28] compared to microscopy (reported as 40 
parasites/uL)[20] would permit higher-density infections to be classified as subpatent. 
Nevertheless, we observed no consistent impact of these sub-RDT infections. 
 
Antenatal P. falciparum infections should offer a unique model by which to investigate the 
individual clinical impact of subpatent infections by means of the analysis of birth outcomes, 
but in light of our null results and those of Williams et al.,[22] what is the biological importance 
of sub-RDT infections? In a longitudinal study of Ugandan children,[29] subpatent P. falciparum 
infections (microscopy-negative and PCR-positive) were not associated with an increased risk of 
clinical disease, relative to uninfected children, suggesting that low-density subpatent 
infections may not presage clinical consequences. One hypothesis for this phenomenon in 
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children is that low-density infections may promote or maintain adaptive immunity to clinical 
disease.[30] By analogy, the presence of subpatent antenatal infections may promote the 
acquisition of immunity to placental-binding parasites, which develops during pregnancy in 
paucigravid Malawian women[31] and which is associated with protection from adverse birth 
outcomes.[32] Notably, although we observed a higher prevalence of placental malaria in 
women with subpatent infections compared to those who were never infected, the prevalence 
of malaria pigment between groups was similar, a finding associated with low birthweight in 
prior studies [23]. Therefore, partial immunity promoted by subpatent parasites could 
potentially attenuate the downstream effects of placental malaria and limit its deleterious 
impact on birthweight. 
 
Our results further highlight the need to prevent patent infections early in pregnancy. 
Compared to uninfected women, those harboring RDT-positive infections at enrollment 
delivered infants with lower birthweights and birthweight-for-age Z-scores, despite being 
treated with DP at that visit and being screened subsequently for parasites with RDTs. In our 
study, women were enrolled between 16 – 24 weeks gestation and there were no associations 
between antenatal or enrollment infections and gestational age, indicating that lower 
birthweights were likely the result of intrauterine growth retardation. Therefore, the 
associations with birthweight likely reflect the vulnerability of the placenta to parasitization 
during the first and early second trimesters, when placental pathology can disrupt the 
trajectory of fetal growth. Currently, with the exception of ITNs, antenatal malaria prevention is 
initiated during the second trimester owing to care-seeking customs, and the contraindication 
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to SP use in the first trimester.[33] Our data, taken together with similar findings in Benin,[20] 
suggest that the risk of LBW and placental malaria may be further reduced by initiating 
preventive measures earlier in pregnancy. This may be enhanced by recent changes to WHO’s 
antenatal care guidelines which now recommend a minimum of eight antenatal care visits and 
encourage contacts at 13 weeks gestation in order to promote IPTp.[34] 
 
Two additional points merit mention. The prevalence of antenatal subpatent infections 
remained largely unchanged, varying between 12 and 14% of women at each scheduled 
antenatal visit; this is in contrast to the prevalence of patent infections, which were most 
common at antenatal enrollment and uncommon thereafter, likely owing to the treatment of 
these RDT-positive women with DP. Although the direct effect of these subpatent infections on 
birth outcomes was not apparent in our study, ongoing gametocytemia may allow these 
women to remain reservoirs of overall malaria transmission. Secondly, the prevalence of 
placental malaria, as detected by microscopy, RDT, PCR, or histology, was 24% in the 242 
women who tested negative by all methods at each visit; by comparison, the prevalence was 
35% in women randomized to IPTp-SP in this study. This suggests that screening and treating in 
the second trimester, using any diagnostic method or treatment, will still result in a large 
proportion of women with placental infection. Therefore, prevention, using bednets and 
routine use of highly-effective prophylaxis or more effective antimalarials such as 
dihydroartemsinin-piperaquine for IPTp, may be more effective measures to reduce placental 
malaria. 
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In this cohort of pregnant Malawian women who were screened three to four times during the 
2nd and 3rd trimester for malaria parasites using RDTs and who did not receive standard 
intermittent preventive antimalarial therapy, antenatal subpatent P. falciparum infections were 
common but not associated with adverse maternal or newborn delivery outcomes. In contrast, 
RDT-positive infections were associated with lower mean birthweights, and more LBW, and this 
association was already apparent at enrollment in the second trimester. These findings suggest 
that higher-density infections may account for the adverse sequelae of antenatal malaria 
infection, and that the prevention of these infections early in pregnancy may offer a new 
strategy to improve existing antenatal care programs in malaria-endemic Africa. 
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Table 1. Impact of infections at enrollment and cumulative antenatal infections on placental histology among 
women with placental malaria 
 
Malaria 
pigment 
present, % 
(n) 
Malaria pigment 
in free 
macrophages, % 
(n) 
Malaria pigment 
within fibrin, % 
(n) 
Intervillous inflammation 
leukocytes, % (n) 
    <5 6-10 11-25 >25 
Infections at enrollment 
Not infected (n=123) 24.4 (30) 0.8 (1) 24.4 (30) 
67.5 
(83) 
23.6 
(29) 
7.3  
(9) 
1.6 
(2) 
RDT-positive infection 
(n=168) 66.7 (112) 1.8 (3) 66.7 (112) 
66.1 
(111) 
28.6 
(48) 
4.8  
(8) 
0.6 
(1) 
Subpatent infection 
(n=43) 20.9 (9) 0 20.9 (9) 
65.1 
(28) 
32.6 
(14) 
2.3  
(1) 
0 
p-value < 0.001 0.558 < 0.001 0.650 
Cumulative antenatal infections 
Never infected (n=56) 8.9 (5) 1.8 (1) 10.7 (6) 
66.1 
(37) 
26.8 
(15) 
7.1  
(4) 0 
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RDT-positive 
infections (n=223) 61.0 (136) 1.4 (3) 61.0 (136) 
66.4 
(148) 
26.9 
(60) 
5.4 
(12) 
1.4 
(3) 
Subpatent infections 
only (n=55) 18.2 (10) 0 16.4 (9) 
67.3 
(37) 
29.1 
(16) 
3.6  
(2) 0 
p-value < 0.001 0.647 < 0.001 0.899 
p-values computed using chi-squared tests. RDT: rapid diagnostic test for malaria parasites. 
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Figure 1. Prevalence of antenatal P. falciparum infections 
 
 
A. Prevalence of uninfected women (green), RDT-positive infections (blue) and subpatent infections 
(turquoise) at enrollment, scheduled visits 1 (1st), 2 (2nd), and 3 (3rd), and unscheduled visits 1 (U1), 2 
(U2), and 3 (U3). Width of columns is proportional to the number of women tested. 
B. Distributions of the numbers of antenatal RDT-positive and subpatent infections. 
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Figure 2. Impacts of RDT-positive and subpatent infections at enrollment and cumulatively during 
pregnancy on continuous birth outcomes 
 
g: grams; dL: deciliter; RDT: rapid diagnostic test for malaria parasites; CI: confidence interval. 
Differences are compared to uninfected women and were computed from pairwise comparisons of means using 
ANOVA. Details for the number of women contributing and the mean values are reported in Supplemental 
Tables 1 and 3. 
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Figure 3. Impacts of RDT-positive and subpatent infections at enrollment and cumulatively during pregnancy on 
dichotomous birth outcomes 
 
Risk ratios computed with Poisson regression and adjusted for gravidity in the aggregated analysis. 
Subpatent infections were defined as RDT-negative and PCR-positive. LBW: low birth weight (< 2500g); 
SGA: small for gestational age; PT: preterm; RDT: rapid diagnostic test for malaria parasites. Maternal 
anemia defined as hemoglobin concentration < 11 grams/deciliter at delivery. Details for the number 
of women contributing, the number of events, and proportions are reported in Supplemental Tables 2 
and 4.  
  
Ac
ce
pte
d M
an
us
cri
pt
 
32 
 
Figure 1A 
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Figure 1B 
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Figure 2 
 
 
  
Ac
ce
pte
d M
an
us
cri
pt
 
36 
 
 
Figure 3 
